

Supplemental Figure 1
TdTomatoTuJ1DAPI

B



# Supplemental Figure 2


E12.5 SOX10Cre; R26R-TdTomato



# $RETCreERT2-EYFP^{Tandem}$

Tamoxifen treatment at E10.5


No tamoxifen treatment




Supplemental Figure 4 Hu SOX10 EYFP B Hu SOX10 **EYFP** Hu NOS1 Hu NOS1 RaraDN Myenteric Plexus RaraDN; RET-CreERT2-EYFP<sup>Tandem</sup> Rara exus Myenteric F RaraDN; RET-CreERT2-EYFPTandem RaraDN Plexus Submucosal plexus CreERT2-EYFP<sup>Tandem</sup> Submucosal RaraDN; RET-RaraDN; RET-


## Supplemental Figure 5

## E11.5 Stomach ENCDC Top 20 genes less abundant in mutant






### E13.5 Colon ENCDC B



#### Top 20 genes more abundant in mutant Fold change (log) Gene



Slc7a11 6.2 6.0 Slc40a1 GaInt3 5.1 Fzd4 4.9 Sema3c 4.9 X9130019022Rik 4.9 4.9 Bhlha15 Bmp4 4.9 4.8 I ifr X1700019G17Rik 4.7 Adam22 4.6 lasf9b 4.6 Enpp2 4.6 Mbnl3 4.6 Prkcq 4.6 Oprl1

Trpc6

Cdh24

Parp9

Rapgef3

0.0007 0.0007 0.00047 0.0041 0.0021 0.009 0.0013 0.0016 4.6 0.00083 4.5 0.0071 4.5 0.0023

4.5

4.4

**FDR** 

**FDR** 

2.1E-07

0.00057

0.0002

0.0006

6.7E-05


0.00052

0.0016


0.003


0.003

# Supplemental Figure 6 E13 Experimental-All Events




CD31 PE-A





-log10(P)

Supplemental Figure 8 Stmn2 Pax3 20 15 Relative fold change (-Log2(∆∆CT)) Relative fold chang (-Log2(∆∆CT)) = 0.0029= 0.003610-10-5-



R26R-TdTomato+

Supplemental Figure 9 RNA-Seq correlates with immunohistochemistry Phox2b Ret 10000 20000 RNA-Seo P = 0.0003P = 0.02338000-15000-6000-10000-Reads from 4000-5000-2000-Control Mutant Control Mutant

Control: *Wnt1Cre+; R26R-TdTomato+*Mutant: *RarαDN<sup>LoxP/+</sup>; Wnt1Cre+; R26R-TdTomato+*